Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00426153 · ClinicalTrials.gov registry record · Phase 2
Octreotide in Severe Polycystic Liver Disease
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00426153: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT00426153 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00426153, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
This study will evaluate the effect of Octreotide LAR® on the liver volumes of patients with severe polycystic liver disease who are not candidates or decline surgical treatments such as liver cyst fenestration, liver resection or liver transplantation. A total of 42 patients will be recruited -14 who will receive placebo and 28 the study drug. Preliminary evidence indicates that this drug is safe and non-toxic in other disease states. Treatment with this drug holds promise not only for individuals with liver involvement, but also for many more patients with polycystic kidney disease.
Interventions
- DRUG Placebo
- DRUG Octreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00426153
The ClinicalTrials.gov registry entry for NCT00426153 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00426153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00426153 about?
NCT00426153 is a clinical study titled "Octreotide in Severe Polycystic Liver Disease". This study will evaluate the effect of Octreotide LAR® on the liver volumes of patients with severe polycystic liver disease who are not candidates or decline surgical treatments such as liver cyst fenestration, liver resection or liver transplantation. A total of 42 patients will be recruited -14 w...
What is the current status of trial NCT00426153?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2007-01. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00426153?
The interventions under investigation include: Placebo (DRUG), Octreotide (DRUG).
Who is sponsoring clinical trial NCT00426153?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.